Hutchison China Meditech (HCM) ORD USD0.10

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Hutchison Chi-Med begins latest trial of fruquintinib
4 September 2020 14:13
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, said on Friday that it has initiated 'FRESCO-2' - a phase 3 registration study of 'fruquintinib' for the treatment of...
-
Hutchison Chi-Med begins phase 1 study of 'HMPL-306'
24 July 2020 15:45
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated a phase 1 study of 'HMPL-306', it announced on Friday, in patients with hematological malignancies in China.
-
Hutchison Chi-Med gets FDA fast track approval for fruquintinib
18 June 2020 09:18
(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Thursday that the US Food and Drug Administration (FDA) has granted 'fast track designation' for the...
-
Hutchison Chi-Med venture to surrender unused land in Guangzhou
9 June 2020 14:06
(Sharecast News) - Hutchison China MediTech, trading as 'Chi-Med', announced on Tuesday that Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company (HBYS) - its 50-50 joint venture with...
-
Hutchison Chi-Med shares up on updated results from 'CALYPSO'
10 February 2020 07:36
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced the availability of updated results from the phase 2 'CALYPSO' study of the savolitinib and 'Imfinzi'...
-
Hutchison Chi-Med upbeat on progress with surufatinib
20 January 2020 16:00
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee of the phase 3 pivotal study of surufatinib in advanced neuroendocrine...
-
Hutchison Chi-Med gets priority review for 'surufatinib' in China
20 December 2019 15:48
(Sharecast News) - Hutchison China MediTech announced on Friday that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted 'Priority...
-
Hutchison China Meditech expands collaboration with Innovent
10 October 2019 15:45
(Sharecast News) - Hutchison China Meditech on Thursday confirmed the expansion of its tumour treatment collaboration agreement with Innovent Biologics Inc..
-
Hutchison Chi-Med initiates latest study of HMPL-523
4 October 2019 15:21
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, has initiated an international phase 1 and 1b study of 'HMPL-523' - its novel spleen tyrosine kinase inhibitor - in patients with...
-
Hutchison China MediTech launches trial for autoimmune disorder treatment
23 August 2019 11:25
(Sharecast News) - Hutchison China MediTech has launched a clinical trial of HMPL-523, a novel spleen tyrosine kinase inhibitor, in patients with immune thrombocytopenia, an autoimmune disorder that can lead...
-
Hutchison Chi-Med makes progress with surufatinib
14 June 2019 14:40
(Sharecast News) - Hutchison China MediTech, trading as Chi-Med, announced on Friday that the independent data monitoring committee (IDMC) of the phase 3 pivotal study of 'surufatinib' in advanced...
-
Hutchison loss widens as China legislation hampers revenue
11 March 2019 11:54
(Sharecast News) - Hutchison China Meditech on Monday reported a drop in sales and increased annual loss after the implementation of new government policy in China.
Company announcements Announcements
-
Vesting of awards under Long Term Incentive Plan
23 April 2021 07:00
Hutchison China Meditech Ltd
-
Notification of Dilution of Voting Rights
14 April 2021 10:30
Hutchison China Meditech Ltd
-
$100m Investment by Baring Private Equity Asia
8 April 2021 08:30
Hutchison China Meditech Ltd
-
Total Voting Rights
31 March 2021 07:00
Hutchison China Meditech Ltd
-
Grant of LTIP Awards and Share Options
29 March 2021 09:30
Hutchison China Meditech Ltd
-
Initiates International Phase I Trials of HMPL-306
29 March 2021 07:00
Hutchison China Meditech Ltd
-
Annual Financial Report
26 March 2021 07:00
Hutchison China Meditech Ltd
-
Agreement to Divest Non-Core OTC Joint Venture
24 March 2021 13:30
Hutchison China Meditech Ltd
-
Phase Ib/II Trial of Surufatinib with Tislelizumab
24 March 2021 07:00
Hutchison China Meditech Ltd
-
Vesting of awards under Long Term Incentive Plan
10 March 2021 07:00
Hutchison China Meditech Ltd
-
Publication of Form 20-F
4 March 2021 15:15
Hutchison China Meditech Ltd
-
Final Results, Business Update and Name Change
4 March 2021 12:00
Hutchison China Meditech Ltd
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2021. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.